Marilyn Martin
Psychiatry · Baltimore, MDNPI 1821014507
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 378 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$919
- Neurocrine Biosciences, Inc.$662
- Lundbeck LLC$647
- Johnson & Johnson$483
- plus $4K from 25 others
Across 25 payments — averaging $8479.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Supernus Pharmaceuticals, Inc.$137K
- Janssen Research & Development, LLC$57K
- Vanda Pharmaceuticals Inc.$19K
What the payments were for
- Food & beverage$9,31498%
- Education$1522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $1,969 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $1,122 |
| Otsuka America Pharmaceutical, Inc. | 36 | $919 |
| Neurocrine Biosciences, Inc. | 24 | $662 |
| Lundbeck LLC | 34 | $647 |
| Johnson & Johnson | 15 | $483 |
| Vanda Pharmaceuticals Inc. | 15 | $479 |
| Axsome Therapeutics, Inc. | 8 | $372 |
| Teva Pharmaceuticals USA, Inc. | 12 | $345 |
| Supernus Pharmaceuticals, Inc. | 5 | $336 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $314 |
| Ironshore Pharmaceuticals Inc. | 11 | $288 |
| Orexo US, Inc. | 18 | $286 |
| Corium, LLC | 8 | $260 |
| Alkermes, Inc. | 10 | $225 |
| Tris Pharma Inc | 8 | $192 |
| Jazz Pharmaceuticals Inc. | 6 | $98 |
| Avanir Pharmaceuticals, Inc. | 5 | $88 |
| Almatica Pharma LLC | 3 | $62 |
| Neos Therapeutics, LP | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Shire North American Group Inc | 2 | $33 |
| Indivior Inc. | 2 | $29 |
| Vertical Pharmaceuticals, LLC | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $13 |
| OWP Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$942
- CAPLYTA$477
- QELBREE$251
- REXULTI$243
- Auvelity$230
- SPRAVATO$127
- Fanapt$125
- Quillivant$121
- Dyanavel XR$121
- Quillichew ER$121
- INGREZZA$119
- Austedo XR$113
How this compares
$9,465 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 48 | $6,676 |
| Quetiapine Fumarate | 46 | $1,228 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $997 |
| Aripiprazole | 24 | $778 |
| Alprazolam | 64 | $657 |
| Buspirone Hcl | 13 | $567 |
| Lamotrigine | 19 | $404 |
| Bupropion XlBupropion Hcl | 22 | $392 |
| Trazodone Hcl | 31 | $301 |
| Gabapentin | 12 | $296 |
| Lorazepam | 45 | $266 |
| Zolpidem Tartrate | 36 | $253 |
| Sertraline Hcl | 13 | $232 |
| Duloxetine Hcl | 21 | $226 |
| Methylphenidate Hcl | 19 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $62 | $23213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.